Observational studyUpdates in surgery2026
Innovative rapid pathological assessment technology for hepatocellular carcinoma following comprehensive treatment guided by indocyanine green fluorescence imaging.
Observational study in Updates in surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundTraditional pathological techniques for diagnosing liver cancer are limited by the need for examination of multiple points. Preoperative treatment can complicate the evaluation by causing tumor necrosis. The evolving treatment landscape requires precise, integrated, and comprehensive management to address the limitations, specifically in localization, sampling, and speed. This study aims to innovatively explore the use of indocyanine green (ICG) fluorescence imaging to guide accurate and rapid localization of residual cancer foci, facilitating rapid pathological sampling and evaluation, termed as rapid pathological technology. PATIENTS AND
methodsIn this prospective and observational study, patients undergoing surgical resection for HCC were enrolled. Traditional evaluation involved specimen fixation, sampling, sectioning, and microscopic observation, while rapid evaluation entailed fluorescence-guided rapid pathological sampling and evaluation post-dissection.
resultsA total of 37 HCC patients were included, and 103 samples of varying fluorescence intensity were collected. Analysis revealed a significant negative correlation between fluorescence intensity and tumor necrosis ratio (ρ = -0.89, p < 0.001). Furthermore, logistic regression modeling yielded an AUC of 0.947, with a specificity of 0.900 and sensitivity of 0.930, indicating strong discriminatory power for tumor necrosis status. An optimal cut-off fluorescence intensity of ≥ 20.5 was identified for predicting partial tumor necrosis. The Youden index is 0.830. Decision curve analysis demonstrated the clinical utility of the prediction model for guiding treatment decisions regarding tumor necrosis.
conclusionsRapid pathological evaluation using ICG fluorescence-guided resection specimens in liver cancer is feasible, enabling effective localization of residual cancer foci and enhancing the accuracy and efficiency of pathological sampling.
trial registrationChiCTR2400082814.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.